Durable Response Rate
Efficacy I PLUVICTO
TROPiCS-02 Results | TRODELVY® (sacituzumab govitecan-hziy) | Official HCP Site
Forest plot of the comparison of overall response rate (ORR).
A) Overall response rate by cohorts. ORR indicates a response of PR or... | Download Scientific Diagram
Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma | PLOS ONE
ODOMZO® (sonidegib) | Efficacy Data
Efficacy data | BENDEKA® (bendamustine HCl) injection
Overall response rate (ORR), overall survival (OS), and... | Download Scientific Diagram
KarMMa Trial ORR | ABECMA® (idecabtagene vicleucel)
ORR Definition: Objective Response Rate | Abbreviation Finder
dMMR Recurrent or Advanced Solid Tumors | JEMPERLI (dostarlimab-gxly)
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology
Pooled analysis of the overall response rate (ORR). | Download Scientific Diagram
ORR (Objective Response Rate) and related statistics – Part 1
Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study | International Journal of Clinical Oncology
Efficacy - Overall Response Rate | Aliqopa US HCP
Objective response rate of placebo in randomized controlled trials of anticancer medicines - eClinicalMedicine
ORR (Objective Response Rate) and related statistics – Part 1
ORR (Objective Response Rate) and related statistics – Part 1
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology
TECARTUS® Clinical Trial Data for R/R Mantle Cell Lymphoma
BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC
Efficacy & Clinical Trial Data | TABRECTA® (capmatinib) tablets
Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis
